GHRP-2 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is GHRP-2?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Growth hormone stimulation, GH deficiency diagnosis, metabolic regulation, neuroprotection, tissue repair, appetite signaling
• International Nonproprietary Name: Pralmorelin
• Molecular Weight: 817.9 g/mol
• Research Status: Approved diagnostic agent in Japan; research use only in most other jurisdictions
• Key Mechanisms: GHS-R1a agonism, protein kinase C activation, calcium influx via voltage-gated channels, PI3K/Akt and ERK1/2 signaling
• Published Studies: Hundreds of preclinical and clinical studies across GH secretion, metabolic, and neuroprotective research areas
• Clinical Trial Status: Used as comparator agent in Phase 3 trials (NCT02229851); diagnostic approval studies completed in Japan
• Regulatory Classification: FDA Category 2 bulk drug substance (not approved therapeutic); WADA S2 prohibited substance; approved diagnostic agent in Japan

What is GHRP-2?

GHRP-2, formally named Growth Hormone-Releasing Peptide-2 and assigned the international nonproprietary name pralmorelin, is a synthetic hexapeptide designed to stimulate growth hormone secretion from the anterior pituitary gland. Researchers classify it as a growth hormone secretagogue (GHS) and a synthetic ghrelin agonist, meaning it activates the same receptor that responds to ghrelin, the body’s endogenous hunger and growth-signaling hormone. The peptide emerged from a series of synthetic compounds developed to understand and replicate ghrelin’s physiological actions at the GHS-R1a receptor. Unlike natural ghrelin, which is a 28-amino acid acylated peptide produced primarily in the stomach, GHRP-2 is a compact six-amino acid synthetic sequence engineered for high receptor affinity and predictable pituitary response. Its compact structure makes it easier to study in controlled research settings than larger endogenous peptides. Interest in GHRP-2 research spans several biological systems. Endocrinologists study it as a diagnostic tool for identifying growth hormone deficiency, particularly because it produces reproducible and quantifiable GH peaks after administration. Metabolic researchers investigate its appetite-stimulating effects, which parallel ghrelin’s well-characterized role in energy balance. Neurologists and cell biologists study its anti-apoptotic and neuroprotective properties across ischemia, diabetes, and inflammatory models. Tissue researchers examine potential roles in wound healing and skeletal muscle recovery. Critically, the majority of GHRP-2 research exists in preclinical settings using animal models and cell cultures. Human research is concentrated in diagnostic protocols and critically ill patient populations. Japan stands alone among major jurisdictions in approving pralmorelin as a clinical diagnostic agent for growth hormone deficiency testing. All other applications remain investigational, and the compound is classified for research use only outside of Japan’s approved diagnostic context.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Property	Specification
Molecular Formula	C45H55N9O6
Molecular Weight	817.9 g/mol
CAS Number	158861-67-7
Amino Acid Sequence	D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2
Peptide Classification	Synthetic hexapeptide; growth hormone secretagogue
Stability	Stable in standard aqueous research buffers; resistant to rapid peptidase degradation
Solubility	Water soluble; compatible with standard physiological buffers

Key Structural Features

GHRP-2’s six-amino acid sequence incorporates several non-natural amino acids, including D-alanine at position one and D-beta-naphthylalanine at position two. These D-amino acid substitutions are deliberate design choices that confer resistance to enzymatic breakdown, extending the peptide’s active research window compared to sequences built entirely from natural L-amino acids. The tryptophan and D-phenylalanine residues in the central and fifth positions are critical for GHS-R1a binding affinity. Structural studies show these aromatic residues engage the receptor’s binding pocket through hydrophobic interactions, contributing to the compound’s high potency at nanomolar concentrations. The C-terminal amidation of the lysine residue further stabilizes the peptide against carboxypeptidase degradation. This structural design distinguishes GHRP-2 from its predecessor GHRP-6 and related compounds GHRP-1 and hexarelin, each of which carries slightly different amino acid compositions that produce distinct receptor binding profiles and downstream signaling characteristics. These structural differences make GHRP-2 a useful research tool for isolating specific aspects of GHS-R1a biology.

Mechanisms of Action Being Investigated

GHRP-2 engages multiple intracellular pathways after binding GHS-R1a, with different signaling cascades predominating depending on the tissue type and experimental model. Researchers have identified at least seven distinct downstream pathways, making this peptide a mechanistically complex research tool rather than a single-target compound.

GHS-R1a Receptor Activation and Primary Signaling

GHS-R1a receptors sit on the surface of pituitary somatotroph cells, hypothalamic neurons, and various peripheral tissues including glial cells, immune cells, and neurons. GHRP-2 acts as a high-affinity synthetic agonist at this receptor, mimicking the endogenous ligand acylated ghrelin. Upon binding, GHS-R1a couples to Gq-type G proteins, initiating downstream signaling cascades. Protein kinase C (PKC) activation represents the primary pathway for growth hormone secretion in pituitary cells. Studies using human GH-secreting tumor cells from acromegaly patients found that GHRP-2 at 10 nM for 30 minutes significantly increased GH secretion via PKC across all seven tumor samples tested, establishing PKC as the dominant secretory trigger in this model [1].

Calcium Influx and Voltage-Gated Channel Involvement

Parallel to PKC activation, GHRP-2 promotes calcium entry into pituitary cells through voltage-gated calcium channels. Research in bovine anterior pituitary cells showed that GHRP-2 across a concentration range of 10 to the minus 13 through 10 to the minus 7 molar stimulated GH secretion through this calcium influx mechanism. The calcium channel blocker nifedipine suppressed this effect, confirming the voltage-gated channel pathway as a distinct and blockable component of GHRP-2’s secretory mechanism [2].

Cyclic AMP Modulation

GHRP-2 modestly elevates cyclic AMP (cAMP) levels in pituitary models but operates independently of protein kinase A (PKA) in several systems. This mechanistic profile differs fundamentally from growth hormone-releasing hormone (GHRH), which relies primarily on cAMP/PKA signaling. The two peptides activate distinct receptors and distinct primary pathways, making their combined use in research models a tool for dissecting separate components of the GH secretory axis [1,2].

PI3K/Akt and ERK1/2 Anti-Apoptotic Pathways

In neural tissue models, GHRP-2 activates phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) pathways. These pathways block programmed cell death by increasing Bcl-2 expression, reducing cytochrome c release from mitochondria, and suppressing caspase-3 activation. Research in cortical neurons under oxygen-glucose deprivation showed that inhibiting either PI3K/Akt or ERK1/2 abolished GHRP-2’s protective effects, confirming both pathways as necessary components of its neuroprotective mechanism [3].

NF-kB Signaling and Mitochondrial Stabilization

In ischemia and reperfusion models, GHRP-2 activates NF-kB signaling to upregulate Bcl-2 and block translocation of apoptosis-inducing factor (AIF) from mitochondria to the nucleus. Uncoupling protein-2 (UCP-2) expression increases in the hippocampus following GHRP-2 treatment, reducing mitochondrial reactive oxygen species production and improving CA1 neuron survival after ischemic insults [3,4].

MAPK Modulation in Glial Cells

In oligodendrocyte and astrocyte models, GHRP-2 reduces p38 MAPK activity while increasing phosphorylated ERK levels. This dual MAPK modulation protects oligodendrocytes from hydrogen peroxide-induced apoptosis and regulates microglial production of pro-nerve growth factor (pro-NGF), a precursor that can promote neuronal death when present in excess. This pathway is particularly relevant to research in diabetic neuropathy and demyelinating disease models [4].

Insulin Signaling and AKT1 Activation

In inflammatory models, GHRP-2 engages insulin signaling pathways through AKT1 activation. This reduces myeloperoxidase activity, lowers apoptosis rates, and decreases oxidative stress markers in tissues exposed to inflammatory stimuli [5]. The pathway links GHRP-2’s receptor biology to broader metabolic and inflammatory regulation beyond pure GH secretion.

Major Areas of Research

GHRP-2 research spans endocrinology, neuroscience, metabolic biology, and tissue repair. Each area draws on the compound’s multi-pathway receptor biology to investigate distinct biological questions.

Growth Hormone Deficiency Diagnosis

The most clinically advanced application for GHRP-2 is growth hormone deficiency (GHD) diagnosis. Japan approved pralmorelin as a diagnostic agent, establishing it as a GH provocative test alongside insulin tolerance tests and arginine stimulation protocols. Diagnostic studies use GHRP-2 administration to generate a measurable GH peak. In subjects with intact pituitary function, GH rises sharply and predictably. In patients with organic GHD, the response is blunted. A 2024 study (PMID 38958228) in adolescents demonstrated the diagnostic utility of this distinction: the non-organic GHD group produced median GH peaks of 88.9 to 90.1 ng/mL, while the organic and genetic GHD group achieved a median peak of only 3.4 ng/mL. The authors noted that current diagnostic cut-off thresholds may need revision to account for this wide response range, as some organic GHD cases risk being misclassified with existing thresholds [6]. In Phase 3 clinical research for somapacitan (NCT02229851), the GHRP-2 tolerance test served as an eligibility criterion using a peak GH cut-off of 9 ng/mL or below for adult GHD diagnosis, demonstrating its accepted role as a research-grade provocative test [7]. Key Research Highlights:

• Median GH peaks of 88.9-90.1 ng/mL in subjects without organic GHD in adolescent diagnostic studies
• Organic/genetic GHD subjects produce median peaks of only 3.4 ng/mL, creating a measurable diagnostic window
• Used as eligibility comparator in Phase 3 adult GHD trials with a 9 ng/mL cut-off threshold

Critically Ill Patient Research

GHRP-2 infusion studies in prolonged critically ill male patients produced some of the most compelling human data for this compound. Critical illness suppresses pulsatile GH secretion and disrupts the somatotropic axis, contributing to muscle wasting, impaired wound healing, and metabolic derangement. Research showed that GHRP-2 infusion reactivated pulsatile GH secretion in this population, normalized insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) levels, and improved metabolic parameters. The studies documented reduced catabolism, lower ureagenesis rates, and decreased markers of bone breakdown. Importantly, GHRP-2 preserved negative feedback inhibition loops in these patients, avoiding the hormone excess associated with exogenous GH administration. This safety-relevant finding distinguishes GHRP-2 from direct GH replacement, which bypasses pituitary feedback entirely [8]. When combined with thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone (GnRH), GHRP-2 also restored thyroid-stimulating hormone (TSH) and luteinizing hormone (LH) axes in the same critically ill population, demonstrating broad somatotropic axis reactivation potential. Key Research Highlights:

• Reactivated pulsatile GH secretion in prolonged critically ill patients
• Normalized IGF-1 and IGFBP-3 with preserved feedback inhibition
• Combined TRH/GnRH protocol restored TSH and LH axes in the same population

Metabolic and Appetite Regulation Research

GHRP-2 mimics ghrelin’s orexigenic (appetite-stimulating) effects through GHS-R1a activation in hypothalamic circuits. In healthy human subjects, GHRP-2 increased food intake by approximately 35% compared to placebo, with subjects reporting subjective hunger enhancement that tracks closely with the known appetite-stimulating profile of endogenous ghrelin [9]. Animal studies using neuropeptide Y (NPY)-deficient mice showed that daily subcutaneous GHRP-2 injections increased body weight, fat mass, food intake, and hypothalamic agouti-related protein (AGRP) mRNA expression. Administration of the melanocortin agonist MT-II prevented the weight gain, identifying the melanocortin signaling axis as a downstream regulator of GHRP-2’s adiposity effects. Notably, these orexigenic effects occurred independently of NPY, confirming that GHRP-2 promotes appetite through NPY-independent ghrelin-like pathways [10]. Key Research Highlights:

• Approximately 35% increase in food intake in healthy human subjects
• Weight, fat mass, and AGRP mRNA increases in NPY-deficient mice
• Weight gain preventable by melanocortin agonist MT-II, implicating melanocortin signaling

Neuroprotective and Cytoprotective Research

Neural protection represents one of the most mechanistically detailed GHRP-2 research areas. GHS-R1a receptors distribute widely in the nervous system, including pituitary cells, hypothalamic neurons, cortical neurons, astrocytes, oligodendrocytes, and microglia. GHRP-2 activates PI3K/Akt and ERK1/2 pathways in these tissues to block apoptotic cascades under multiple stress conditions. In cortical neuron models under oxygen-glucose deprivation, GHRP-2 reduced programmed cell death through Bcl-2 upregulation and caspase-3 suppression. In hippocampal ischemia models, UCP-2 upregulation reduced mitochondrial oxidative stress and improved CA1 neuron survival. In diabetic models, GHRP-2 promoted astrocyte proliferation and oligodendrocyte survival through PI3K/Akt signaling, while also normalizing the NGF/pro-NGF balance that contributes to diabetic neuropathy [3,4]. Related ghrelin agonists GHRP-6 and ghrelin itself show parallel neuroprotective effects in ischemia models, and researchers extrapolate mechanistic findings between these compounds due to shared GHS-R1a receptor engagement. Key Research Highlights:

• Anti-apoptotic effects in cortical neurons under oxygen-glucose deprivation via PI3K/Akt and ERK1/2
• UCP-2 upregulation and CA1 neuron protection in hippocampal ischemia models
• Oligodendrocyte protection from oxidative stress and normalized NGF/pro-NGF balance in diabetic models

Anti-Inflammatory Research

GHRP-2 demonstrated anti-inflammatory properties in several preclinical models. At 100 micrograms per kilogram body weight, the peptide reduced macrophage activity and inflammatory symptom severity in arthritis models. In lipopolysaccharide-challenged rats, GHRP-2 attenuated systemic inflammatory markers and reduced oxidative stress in cultured cells exposed to inflammatory stimuli [5]. The mechanistic basis for these effects involves multiple pathways: AKT1 activation reduces myeloperoxidase activity (a marker of neutrophil-driven inflammation), PKC and PKA modulation dampens inflammatory signaling in pituitary and immune cells, and NF-kB pathway engagement shifts the cellular response toward survival rather than inflammatory death programs. Key Research Highlights:

• Anti-arthritic effects at 100 mcg/kg with reduced macrophage activity
• Attenuated inflammatory markers in LPS-challenged animal models
• Myeloperoxidase reduction via AKT1 activation suggesting neutrophil-mediated inflammation suppression

Tissue Regeneration and Repair Research

GHRP-2’s growth hormone-stimulating effects cascade downstream through IGF-1 and mTOR-related anabolic signaling pathways, creating secondary effects relevant to tissue repair research. GH and IGF-1 promote protein synthesis, extracellular matrix production, and cellular proliferation across multiple tissue types. Researchers investigate GHRP-2 for skeletal muscle regeneration, particularly because the compound’s pituitary-mediated GH release preserves feedback mechanisms that direct GH replacement bypasses. Intranasal administration studies in pediatric subjects showed modest improvements in growth velocity with doses of 5 to 20 micrograms per kilogram, reported as well tolerated across the study period [11]. A one-year intranasal application study in a patient with anorexia nervosa showed no reported safety concerns in available published data, though this represents a single case with limited generalizability. Research in growth-retarded yak animals found that GHRP-2 administration did not significantly alter myostatin mRNA or muscle RING-finger protein-1 (MuRF1) mRNA levels in longissimus dorsi or semitendinosus muscles despite activating GHS-R receptors and stimulating systemic GH. This finding highlights a disconnect between systemic GH stimulation and local muscle gene regulation that researchers consider an important mechanistic limitation [12]. Key Research Highlights:

• Modest growth velocity improvements with intranasal administration in pediatric research subjects
• No detectable myostatin or MuRF1 mRNA changes in yak muscle studies despite GHS-R activation
• mTOR-related anabolic signaling investigated as downstream mechanism for tissue effects

Combination Studies and Synergistic Research

GHRP-2 research frequently incorporates combination protocols with GHRH, TRH, and GnRH to examine additive or synergistic effects on multiple endocrine axes. GHRH acts through a distinct receptor (the GHRH receptor) using cAMP/PKA as its primary pathway, while GHRP-2 uses GHS-R1a and primarily PKC, making the two compounds mechanistically complementary rather than redundant. Combined GHRP-2 and GHRH administration produces larger GH responses than either agent alone in most study models. This additive effect forms the basis for combination provocative testing protocols and for research examining complete somatotropic axis reactivation in disease states. The triple combination of GHRP-2, TRH, and GnRH in critically ill patients produced broader hormonal restoration than GHRP-2 alone, restoring TSH and LH in addition to GH axis function [8]. GHRP-2 has also been detected at approximately 50 micrograms per capsule in commercially available dietary supplements via mass spectrometry analysis. This finding raises both anti-doping concerns given the compound’s WADA S2 classification and consumer safety questions about undisclosed peptide content in unregulated products [13]. Key Research Highlights:

• Additive GH response when combined with GHRH through complementary receptor mechanisms
• Triple combination with TRH and GnRH restored GH, TSH, and LH axes in critically ill patients
• Detected at approximately 50 mcg per capsule in dietary supplement mass spectrometry analysis

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

GHRP-2 is most commonly studied via subcutaneous and intravenous routes in preclinical and clinical research models. Both routes produce measurable GH peaks within 15 to 30 minutes of administration, with maximal GH concentrations typically achieved at 30 to 60 minutes post-dose. Intranasal administration has been investigated in pediatric populations and shows systemic absorption sufficient to produce detectable GH responses, though with reduced bioavailability compared to injectable routes. Oral bioavailability is limited by gastrointestinal peptidase activity. While the D-amino acid substitutions in GHRP-2’s sequence confer some enzymatic resistance compared to fully natural L-peptides, oral studies have generally produced inconsistent results, and oral administration is not a primary focus of current research protocols.

Distribution and Metabolism

GHS-R1a receptors distribute across multiple tissues, and GHRP-2’s effects extend beyond the pituitary. The compound crosses the blood-brain barrier, with studies confirming nervous system penetration and receptor engagement in hypothalamic and cortical tissue. Peripheral receptor engagement occurs in immune cells, adipose tissue, and gastric mucosa. Plasma half-life for GHRP-2 in animal models ranges from approximately 15 to 60 minutes depending on the species and administration route, consistent with the relatively brief pharmacokinetic profiles typical of synthetic hexapeptides. The non-natural D-amino acid residues extend this window modestly compared to all-natural sequences.

Delivery Methods Under Investigation

• Subcutaneous injection: The most common route in animal and human research; produces reliable GH peaks within 30-60 minutes
• Intravenous infusion: Used in critically ill patient studies; enables controlled dose titration and continuous administration protocols
• Intranasal administration: Studied in pediatric growth research at 5-20 mcg/kg; non-invasive but lower bioavailability
• Intraperitoneal injection: Standard route in rodent models for rapid systemic distribution

Excretion and Clearance

GHRP-2 undergoes standard peptide metabolism through endopeptidase and exopeptidase activity in plasma and peripheral tissues. Degradation products are renally cleared. The compound’s rapid plasma clearance relative to its biological effects suggests that downstream GH and IGF-1 elevation persists well beyond the peptide’s own plasma half-life, creating a biological effect window longer than the pharmacokinetic window would predict. Response efficacy decreases in obese individuals and with advanced age, reflecting changes in pituitary somatotroph responsiveness and altered GHS-R1a signaling in these populations. This efficacy attenuation represents a relevant pharmacodynamic consideration for any research modeling age-related or obesity-related GH axis dysfunction.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data Most GHRP-2 research derives from animal models and cell culture studies. Human data concentrates in two specific contexts: diagnostic GH provocative testing and critically ill patient infusion studies. General human safety and efficacy data across the compound’s full range of investigated applications is absent. Long-term human effects beyond individual study durations are completely uninvestigated. GH response attenuates significantly in obese subjects and older adults, creating populations where diagnostic utility is compromised and where research findings from lean, younger animal models may not apply. The 2024 adolescent diagnostic study suggested current cut-off thresholds may misclassify some patients, highlighting that even the compound’s most clinically advanced application requires ongoing refinement [6]. Mechanistic Gaps The receptor for des-acylated ghrelin (which shares some structural features with GHRP-2’s target system) has not been characterized. GHRP-2’s demonstrated partial engagement of GRF receptors alongside GHS-R1a suggests a multireceptor profile whose full biological implications are incompletely understood. The disconnect between systemic GH stimulation and downstream muscle gene expression changes (demonstrated in yak studies) indicates that GH elevation alone does not guarantee proportional anabolic signaling at the tissue level [12]. Methodological Considerations

• Most mechanistic studies use single-dose or acute administration protocols; chronic administration effects require separate investigation
• Species variation in GHS-R1a distribution and signaling creates translation challenges between rodent, bovine, and human research
• Combination studies with GHRH, TRH, and GnRH complicate attribution of effects to GHRP-2 specifically
• Dietary supplement contamination data raises questions about uncontrolled exposure in human populations, complicating interpretation of any self-reported human case data

Areas Needing Further Investigation

• Long-term safety profile with repeated administration in healthy human subjects: completely unstudied
• Human neuroprotection data: all current evidence extrapolated from animal and cell culture models
• Optimal combination ratios with GHRH and other somatotropic agents for specific research applications
• Anti-inflammatory mechanisms in humans: preclinical findings have not been translated to human trials
• Tissue-level anabolic signaling downstream of GHRP-2-stimulated GH: the gap identified in yak muscle studies needs investigation in mammalian and human tissue models

Regulatory and Research Status

Current Classification

FDA Status The FDA classifies GHRP-2 as a Category 2 bulk drug substance under the 503A and 503B compounding pharmacy regulations. This classification means the compound is not approved for general therapeutic use and is not permitted in compounded preparations for human administration outside of narrow regulatory exceptions. GHRP-2 is not an approved drug in the United States for any indication. Japan (Pralmorelin) Japan represents the only major jurisdiction with formal regulatory approval for GHRP-2 clinical use. The compound is approved as a diagnostic agent for growth hormone deficiency testing under the name pralmorelin, restricted to provocative testing protocols in clinical diagnostic settings. WADA Status The World Anti-Doping Agency prohibits GHRP-2 under the S2 category: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. This prohibition applies in and out of competition. Mass spectrometry studies detecting GHRP-2 in dietary supplements at approximately 50 micrograms per capsule raise serious anti-doping concerns, as athletes could be inadvertently exposed to a prohibited substance through contaminated products [13]. Athletes subject to anti-doping testing under any WADA-compliant authority must not use GHRP-2 regardless of administration route or source. International Perspective The European Medicines Agency (EMA) has not approved GHRP-2 for any human therapeutic application. Most major regulatory authorities follow research-chemical classification. Veterinary applications vary by jurisdiction, with some regions permitting use in livestock research under appropriate institutional oversight.

Research Community Approach

Active GHRP-2 research continues primarily in academic and clinical research institutions. The compound’s approved diagnostic role in Japan provides a regulatory framework that supports controlled human research in that jurisdiction. Elsewhere, institutional review board approval and appropriate biosafety oversight govern legitimate research use. The compound’s WADA prohibition adds anti-doping compliance obligations for any research involving competitive athletes.

Future Research Directions

The clearest path forward for GHRP-2 research involves dedicated human pharmacokinetic studies, long-term safety profiling, and properly controlled clinical trials for applications beyond GH deficiency diagnosis. The neuroprotection and anti-inflammatory findings from preclinical models represent the largest unmet translational gap, as these mechanisms have not been tested in human subjects. Standardizing diagnostic cut-off thresholds for the provocative test application, as suggested by recent adolescent research, represents a near-term refinement with direct clinical relevance.

Key Research Findings

PKC-Dependent GH Secretion in Human Acromegaly Tumor Cells

Research Focus: Identifying primary intracellular pathways driving GH secretion after GHRP-2 exposure Key Results: GHRP-2 at 10 nM for 30 minutes significantly increased GH secretion via PKC activation across all seven acromegalic tumor samples tested; cAMP levels rose modestly but PKA was not the primary effector; GHRP-2 and GHRH operated through distinct, non-overlapping receptor systems Significance: Established PKC as the primary secretory trigger in human pituitary cells and demonstrated mechanistic independence from GHRH, providing a rationale for combined use in research protocols Limitations: Tumor-derived cells differ from healthy pituitary somatotrophs; results may not translate directly to normal GH physiology [1]

Calcium Channel-Dependent GH Release in Bovine Pituitary Cells

Research Focus: Characterizing calcium-dependent pathways in GHRP-2-induced GH secretion Key Results: GHRP-2 concentrations from 10 to the minus 13 through 10 to the minus 7 molar stimulated GH secretion through voltage-gated calcium channel influx; nifedipine blocked this effect; partial GRF receptor involvement also identified alongside the primary GHS-R1a mechanism Significance: Confirmed calcium influx as a distinct, blockable component of GH secretion and revealed a multireceptor engagement profile with implications for understanding GHS-R1a biology Limitations: Bovine pituitary cells; species differences in GHS-R1a signaling limit direct extrapolation to human physiology [2]

GH Axis Reactivation in Critically Ill Patients

Research Focus: Restoring pulsatile GH secretion and normalizing somatotropic axis function in prolonged critical illness Key Results: GHRP-2 infusion reactivated pulsatile GH secretion, normalized IGF-1 and IGFBP-3, reduced catabolism and ureagenesis, decreased bone breakdown markers, and preserved pituitary feedback inhibition; combination with TRH and GnRH additionally restored TSH and LH axes Significance: Demonstrated clinically meaningful somatotropic axis restoration without feedback bypass, distinguishing GHRP-2 from exogenous GH administration; provided a human safety finding relevant to therapeutic development Limitations: Studied in a specific critically ill male population; generalizability to other patient populations requires dedicated investigation [8]

Adolescent GH Deficiency Diagnostic Study

Research Focus: Evaluating GHRP-2 as a GH provocative test agent and assessing adequacy of existing diagnostic cut-offs in adolescents Key Results: Non-organic GHD subjects produced median GH peaks of 88.9 to 90.1 ng/mL; organic/genetic GHD subjects produced a median peak of only 3.4 ng/mL; authors identified potential misclassification risk with current diagnostic thresholds Significance: Supported diagnostic utility while identifying need for threshold refinement; represents current human diagnostic research guiding pralmorelin’s approved clinical application Limitations: Single study cohort; cut-off revision recommendations require validation in larger multi-center diagnostic trials [6]

Neuroprotective Effects via PI3K/Akt and ERK1/2 in Neural Models

Research Focus: Identifying mechanisms underlying GHRP-2’s anti-apoptotic effects in neural tissue under metabolic and ischemic stress Key Results: PI3K/Akt and ERK1/2 inhibition abolished anti-apoptotic effects in cortical neurons under oxygen-glucose deprivation; Bcl-2 upregulated, cytochrome c release and caspase-3 activation suppressed; UCP-2 upregulation in hippocampus reduced reactive oxygen species and improved CA1 neuron survival; oligodendrocyte protection from hydrogen peroxide toxicity confirmed Significance: Established mechanistic basis for neuroprotection across multiple neural cell types and stress models, identifying GHRP-2 as a research tool for studying GHS-R1a biology in the nervous system Limitations: All findings from animal models and cell cultures; no human neuroprotection data exists [3,4]

Metabolic and Orexigenic Effects in Human Subjects

Research Focus: Characterizing GHRP-2’s appetite-stimulating effects in healthy human volunteers Key Results: Food intake increased approximately 35% compared to placebo; subjects reported subjective hunger; effects parallel known ghrelin orexigenic profile; NPY-deficient mouse studies confirmed NPY-independent appetite promotion through AGRP and melanocortin pathways Significance: Established clear human orexigenic activity linked mechanistically to GHS-R1a ghrelin mimicry; relevant to research in appetite disorders and cachexia models Limitations: Short-term feeding studies; chronic appetite and metabolic effects in humans require longitudinal investigation; orexigenic effects may counteract GH-mediated body composition benefits in some models [9,10]

Absence of Muscle Gene Expression Changes in Yak Growth Model

Research Focus: Testing whether GHRP-2-mediated GH stimulation produces downstream muscle anabolic gene changes in growth-retarded animals Key Results: Daily GHRP-2 administration did not significantly alter myostatin mRNA or MuRF1 mRNA in longissimus dorsi or semitendinosus muscles despite confirmed GHS-R activation; P values exceeded 0.05 for all muscle gene measurements Significance: Identified a critical disconnect between systemic GH stimulation and local muscle gene regulation; tempers assumptions that GH elevation directly translates to muscle-level anabolic signaling Limitations: Yak is a non-standard research model; whether this finding extends to rodent or human skeletal muscle requires direct investigation [12]

Frequently Asked Questions

What is GHRP-2 and why do researchers study it?

GHRP-2 is a synthetic six-amino acid peptide that stimulates growth hormone release by activating GHS-R1a receptors on pituitary cells. Researchers study it because it produces reliable, measurable GH peaks that make it useful as a diagnostic tool for growth hormone deficiency, and because its receptor biology intersects with appetite regulation, neuroprotection, and tissue repair pathways that are active research areas.

Is GHRP-2 the same as ghrelin?

GHRP-2 is not the same as ghrelin but activates the same primary receptor, GHS-R1a. Natural ghrelin is a 28-amino acid acylated peptide produced mainly in the stomach. GHRP-2 is a synthetic six-amino acid compound engineered for high receptor binding affinity. The two compounds share orexigenic and GH-stimulating effects through this shared receptor but differ in size, structure, origin, and metabolic profile.

Has GHRP-2 been approved for any medical use?

Japan is the only major jurisdiction to formally approve GHRP-2 (under the name pralmorelin) for clinical use, specifically as a diagnostic agent for growth hormone deficiency testing. It is not approved for therapeutic use in the United States, the European Union, or most other countries. Outside Japan’s diagnostic context, GHRP-2 is classified as a research chemical.

How does GHRP-2 differ from GHRH in research?

GHRP-2 and GHRH stimulate GH secretion through entirely different receptors and primary signaling pathways. GHRP-2 activates GHS-R1a and primarily uses protein kinase C signaling. GHRH activates the GHRH receptor and relies on cyclic AMP and protein kinase A signaling. This mechanistic difference makes them complementary research tools: they can be studied separately to isolate specific components of GH axis biology or combined to study additive effects.

Is GHRP-2 prohibited in competitive sports?

Yes. The World Anti-Doping Agency prohibits GHRP-2 under its S2 category covering peptide hormones, growth factors, related substances, and mimetics. This prohibition applies both in and out of competition. Mass spectrometry studies have detected GHRP-2 in commercial dietary supplements, raising concerns that athletes could receive inadvertent exposure through contaminated products. Any athlete subject to anti-doping testing should treat GHRP-2 as a prohibited substance regardless of source.

References

1. Popovic, V., et al. (1994). Growth hormone-releasing peptide-2 (GHRP-2) selectively and stimulates growth hormone secretion via protein kinase C in human GH-secreting adenomas. Journal of Clinical Endocrinology and Metabolism, 79(4), 1026-1031. PubMed
2. Deghenghi, R., et al. (1994). GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences, 54(18), 1321-1328. PubMed
3. Chung, H., et al. (2011). Growth hormone-releasing peptide-2 (GHRP-2) activates ERK1/2 and PI3K/Akt in cortical neurons under oxygen-glucose deprivation. Brain Research, 1423, 94-101. PubMed
4. Bitar, M.S., et al. (2012). Ghrelin and growth hormone-releasing peptides modulate the GHS-R1a/PI3K signaling balance between NGF and pro-NGF in the diabetic peripheral nervous system. Endocrinology, 153(9), 4442-4455. PubMed
5. Granado, M., et al. (2005). Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. American Journal of Physiology – Endocrinology and Metabolism, 288(3), E486-E492. PubMed
6. Oiso, Y., et al. (2024). Pralmorelin (GHRP-2) provocative test for growth hormone deficiency in adolescents: Evaluation of diagnostic thresholds and response patterns. Clinical Endocrinology, advance online. PubMed
7. Johannsson, G., et al. (2018). Somapacitan, a reversible albumin-binding GH derivative, in adult GH deficiency: A randomized phase 3 trial. Journal of Clinical Endocrinology and Metabolism, 103(9), 3145-3156. PubMed
8. Peeters, R.P., et al. (2004). Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with disease severity and mortality. Journal of Clinical Endocrinology and Metabolism, 89(1), 413-420. PubMed
9. Laferrere, B., et al. (2005). Effect of GHRP-2 on appetite and food intake in healthy subjects. Journal of Clinical Endocrinology and Metabolism, 90(2), 611-616. PubMed
10. Shuto, Y., et al. (2002). Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. Journal of Clinical Investigation, 109(11), 1429-1436. PubMed
11. Loche, S., et al. (1997). Growth velocity and growth hormone responses after intranasal administration of growth hormone-releasing peptide-2 in children with growth hormone deficiency. Journal of Pediatrics, 131(3), 435-438. PubMed
12. Wang, J., et al. (2019). Effects of GHRP-2 on growth performance and expression of growth-related genes in yak. Animal Science Journal, 90(8), 1023-1031. PubMed
13. Thevis, M., et al. (2012). Detection of the growth hormone secretagogue GHRP-2 in dietary supplements. Drug Testing and Analysis, 4(9), 715-720. PubMed
14. Bowers, C.Y., et al. (1994). Xenobiotic growth hormone-releasing peptides and the growth hormone-releasing hormone receptor. Endocrinology, 135(5), 1734-1745. PubMed
15. Van den Berghe, G., et al. (1999). Growth hormone secretagogues in critical illness. Trends in Endocrinology and Metabolism, 10(6), 228-234. PubMed
16. Arvat, E., et al. (2000). Mechanisms underlying the increase in plasma GH secretion by GH-releasing peptides in normal subjects. Growth Hormone and IGF Research, 10(1), 1-8. PubMed
17. Kojima, M., et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656-660. PubMed
18. Muccioli, G., et al. (2004). Growth hormone secretagogues and ghrelin: how they modulate the GH system. European Journal of Pharmacology, 490(1-3), 1-14. PubMed
19. Nass, R., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601-611. PubMed
20. Howard, A.D., et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974-977. PubMed